Mirador Therapeutics
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases
$250MSeries B
Role not disclosedI
Invus
Activity from announced rounds
Activity in this selectionUnited States · Jan 31, 2026 · Jan 1, 2026
Invus is the investment-firm name used by Encoded Therapeutics and in LifeMine transaction-counsel coverage.
Recorded funding activity
Encoded develops precision gene therapies for neurological disorders. LifeMine uses fungal genomes for drug discovery, while City develops RNA-interference medicines. The records identify different therapeutic approaches without substituting an unnamed parent or fund.
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $555M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionParabilis Medicines
Develops medicines targeting historically undruggable protein targets in cancer
$305MSeries F
Role not disclosed